Seeking Alpha

Sarepta Therapeutics (SRPT) gets a 3% premarket lift from an initiation at Needham (Buy)....

Sarepta Therapeutics (SRPT) gets a 3% premarket lift from an initiation at Needham (Buy). Analyst Chad Messer is positive on eteplirsen and says he believes "the market reacted inappropriately to last week's regulatory update." The FDA requested "additional information" last Monday in order to evaluate an Accelerated Approval application, news the market did not like. (See also: Leerink Swann uncertain about SRPT)
Comments (1)
  • pat walsh
    , contributor
    Comments (263) | Send Message
     
    I thought the request by the FDA was good news.We shall see.
    22 Apr 2013, 09:05 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector